One-year clinical experience on the use of Nintedanib in systemic sclerosis
© 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology..
We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Respirology case reports - 11(2023), 6 vom: 19. Juni, Seite e01120 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Magnani, Luca [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Autoimmunity |
|---|
| Anmerkungen: |
Date Revised 28.05.2023 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/rcr2.1120 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357316487 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357316487 | ||
| 003 | DE-627 | ||
| 005 | 20231226072327.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/rcr2.1120 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357316487 | ||
| 035 | |a (NLM)37229296 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Magnani, Luca |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a One-year clinical experience on the use of Nintedanib in systemic sclerosis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.05.2023 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. | ||
| 520 | |a We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a autoimmunity | |
| 650 | 4 | |a fibrosis | |
| 650 | 4 | |a interstitial lung disease | |
| 650 | 4 | |a rare disease | |
| 650 | 4 | |a systemic sclerosis | |
| 700 | 1 | |a Spinella, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Testoni, Sofia |e verfasserin |4 aut | |
| 700 | 1 | |a Lumetti, Federica |e verfasserin |4 aut | |
| 700 | 1 | |a Scelfo, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Dardani, Lucia |e verfasserin |4 aut | |
| 700 | 1 | |a Bajocchi, Gianluigi |e verfasserin |4 aut | |
| 700 | 1 | |a Clini, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Giuggioli, Dilia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respirology case reports |d 2013 |g 11(2023), 6 vom: 19. Juni, Seite e01120 |w (DE-627)NLM244269440 |x 2051-3380 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:6 |g day:19 |g month:06 |g pages:e01120 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/rcr2.1120 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 6 |b 19 |c 06 |h e01120 | ||